Mucosal leishmaniasis and miltefosine [7]

Clinical Infectious Diseases

Volumn 44, Issue 11, 2007, Pages 1525-1526

  Tuon, Felipe Francisco ^a   Amato, Valdir Sabbaga ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; MILTEFOSINE; PLACEBO;

CLINICAL TRIAL; DEVELOPED COUNTRY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; HUMAN; LEISHMANIASIS; LETTER; MUCOSAL LEISHMANIASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TOURISM;

ANIMALS; ANTIPROTOZOAL AGENTS; HUMANS; LEISHMANIA; LEISHMANIASIS, MUCOCUTANEOUS; PHOSPHORYLCHOLINE;

EID: 34249079184     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/517848     Document Type: Letter

References (6)

1. Amato VS, Tuon FF, Campos A, et al. Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B. Clin Infect Dis 2007; 44:311-2.
2. Jha TK, Sundar S, Thakur CP, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341:1795-800.
3. Soto J, Arana BA, Toledo J, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38:1266-72.
4. Amato VS, Tuon FF, Siquiera AM, et al. Treatment of mucosal leishmaniasis in Latin America - a systematic review. Am J Trop Med Hyg (in press).
5. Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimoniate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis 1994; 18:381-4.
6. Soto J, Toledo J, Valda L, et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin Infect Dis 2007; 44:350-6.